Elenestinib
PreclinicalSmall molecule
Elenestinib is one of 21 small molecule programs targeting Systemic Mastocytosis. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Systemic Mastocytosis
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Leustatin
EMD SeronoApproved
Prolia
AmgenPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Rydapt
NovartisPhase 2
Adcetris
PfizerPhase 2
17-AAG
Bristol-Myers SquibbPhase 2
Masitinib
AAB Science
Phase 3
Ayvakit
BBlueprint Medicines
Phase 2
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Elenestinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBlueprint Medicines